Cargando…

Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma

More than 100 protostane triterpenoids have been isolated from the dried rhizomes of Alisma species, designated Alismatis rhizoma (AR), commonly used in Asian traditional medicine to treat inflammatory and vascular diseases. The main products are the alisols, with the lead compounds alisol-A/-B and...

Descripción completa

Detalles Bibliográficos
Autor principal: Bailly, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406200/
https://www.ncbi.nlm.nih.gov/pubmed/36009492
http://dx.doi.org/10.3390/biomedicines10081945
_version_ 1784774064406003712
author Bailly, Christian
author_facet Bailly, Christian
author_sort Bailly, Christian
collection PubMed
description More than 100 protostane triterpenoids have been isolated from the dried rhizomes of Alisma species, designated Alismatis rhizoma (AR), commonly used in Asian traditional medicine to treat inflammatory and vascular diseases. The main products are the alisols, with the lead compounds alisol-A/-B and their acetate derivatives being the most abundant products in the plant and the best-known bioactive products. The pharmacological effects of Ali-A, Ali-A 24-acetate, Ali-B, Ali-B 23-acetate, and derivatives have been analyzed to provide an overview of the medicinal properties, signaling pathways, and molecular targets at the origin of those activities. Diverse protein targets have been proposed for these natural products, including the farnesoid X receptor, soluble epoxide hydrolase, and other enzymes (AMPK, HCE-2) and functional proteins (YAP, LXR) at the origin of the anti-atherosclerosis, anti-inflammatory, antioxidant, anti-fibrotic, and anti-proliferative activities. Activities were classified in two groups. The lipid-lowering and anti-atherosclerosis effects benefit from robust in vitro and in vivo data (group 1). The anticancer effects of alisols have been largely reported, but, essentially, studies using tumor cell lines and solid in vivo data are lacking (group 2). The survey shed light on the pharmacological properties of alisol triterpenoids frequently found in traditional phytomedicines.
format Online
Article
Text
id pubmed-9406200
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94062002022-08-26 Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma Bailly, Christian Biomedicines Review More than 100 protostane triterpenoids have been isolated from the dried rhizomes of Alisma species, designated Alismatis rhizoma (AR), commonly used in Asian traditional medicine to treat inflammatory and vascular diseases. The main products are the alisols, with the lead compounds alisol-A/-B and their acetate derivatives being the most abundant products in the plant and the best-known bioactive products. The pharmacological effects of Ali-A, Ali-A 24-acetate, Ali-B, Ali-B 23-acetate, and derivatives have been analyzed to provide an overview of the medicinal properties, signaling pathways, and molecular targets at the origin of those activities. Diverse protein targets have been proposed for these natural products, including the farnesoid X receptor, soluble epoxide hydrolase, and other enzymes (AMPK, HCE-2) and functional proteins (YAP, LXR) at the origin of the anti-atherosclerosis, anti-inflammatory, antioxidant, anti-fibrotic, and anti-proliferative activities. Activities were classified in two groups. The lipid-lowering and anti-atherosclerosis effects benefit from robust in vitro and in vivo data (group 1). The anticancer effects of alisols have been largely reported, but, essentially, studies using tumor cell lines and solid in vivo data are lacking (group 2). The survey shed light on the pharmacological properties of alisol triterpenoids frequently found in traditional phytomedicines. MDPI 2022-08-11 /pmc/articles/PMC9406200/ /pubmed/36009492 http://dx.doi.org/10.3390/biomedicines10081945 Text en © 2022 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bailly, Christian
Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma
title Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma
title_full Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma
title_fullStr Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma
title_full_unstemmed Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma
title_short Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma
title_sort pharmacological properties and molecular targets of alisol triterpenoids from alismatis rhizoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406200/
https://www.ncbi.nlm.nih.gov/pubmed/36009492
http://dx.doi.org/10.3390/biomedicines10081945
work_keys_str_mv AT baillychristian pharmacologicalpropertiesandmoleculartargetsofalisoltriterpenoidsfromalismatisrhizoma